Vericel Corporation to Participate in Healthcare Conference
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for sports medicine and severe burn care, has announced its upcoming participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. This event will take place on September 6, where President and CEO Nick Colangelo, along with CFO Joe Mara, will take part in a fireside chat at 1:05 p.m. ET.
About Vericel Corporation
Vericel is well-known for its commitment to developing groundbreaking therapies that meet critical medical needs in the fields of sports medicine and severe burn care. With a strong focus on innovation, the company combines biological science with state-of-the-art medical technologies, resulting in a diverse portfolio of advanced cell therapies and specialty biologics aimed at repairing injuries and enhancing patients' lives.
Innovative Product Offerings
The company proudly offers a remarkable trio of products in the United States. One of these is MACI®, which stands for autologous cultured chondrocytes on porcine collagen membrane. This advanced cellular scaffold product is specifically indicated for repairing full-thickness cartilage defects in the knees of adult patients. It represents a significant advancement in orthopedic treatments, offering a regenerative solution for individuals dealing with cartilage deterioration.
Epicel®
Another crucial product from Vericel is Epicel®, a permanent skin replacement option for patients suffering from deep dermal or full-thickness burns that cover 30% or more of their total body surface area. This treatment is vital for the recovery and rehabilitation of burn victims.
NexoBrid®
Additionally, Vericel has exclusive rights to NexoBrid®, an innovative biological orphan product that contains proteolytic enzymes. This treatment is specifically designed for effective eschar removal in both adult and pediatric patients with deep partial-thickness and/or full-thickness burns. NexoBrid® not only accelerates healing but also enhances patient outcomes, further demonstrating Vericel's dedication to advanced medical care.
Company Growth and Future Goals
As Vericel Corporation continues to evolve, it stands at the forefront of the regenerative medicine sector, tackling complex healthcare challenges with its expertly crafted therapies. Its ongoing participation in significant healthcare forums like the Morgan Stanley Conference highlights the company's commitment to engaging with investors and stakeholders about its advancements and strategic vision for innovative solutions.
Contact Information for Investors and Media
For more information, investors can contact Eric Burns at ir@vcel.com or by phone at +1 (734) 418-4411. Media inquiries can be directed to Julie Downs at media@vcel.com. This direct communication is essential for fostering relationships with stakeholders and keeping the public informed about the company’s progress.
Frequently Asked Questions
What is Vericel Corporation known for?
Vericel Corporation specializes in advanced therapies for sports medicine and severe burn care, focusing on regenerative solutions.
When is Vericel presenting at the Morgan Stanley Global Healthcare Conference?
Vericel will present at the conference on September 6 at 1:05 p.m. ET.
What products does Vericel offer?
Vericel markets several products including MACI®, Epicel®, and has rights to NexoBrid®.
How can investors contact Vericel?
Investors can reach Eric Burns through ir@vcel.com or by calling +1 (734) 418-4411.
Where can I find more information about Vericel?
More information can be found on Vericel’s official website under the Investor Relations section.